Rat Anti-MYBPC3 (AA 2-169) Recombinant Antibody (CBFYM-2876) (CBMAB-M3070-FY)

Go to compare Compare Online Inquiry
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal
Rat
Clone
CBFYM-2876
Application
WB
Immunogen
Recombinant mouse MyBPC3, Pro2-Ser169
Specificity
Mouse
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Lyophilized
Buffer
PBS
Concentration
LYOPH
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Epitope
AA 2-169
More Infomation

Target

Full Name
MYOSIN BINDING PROTEIN C, CARDIAC
Introduction
MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone of A bands in striated muscle. MYBPC3, the cardiac isoform, is expressed exclussively in heart muscle. Regulatory phosphorylation of the cardiac isoform in vivo by cAMP-dependent protein kinase upon adrenergic stimulation may be linked to modulation of cardiac contraction. Mutations in MYBPC3 are one cause of familial hypertrophic cardiomyopathy.
Entrez Gene ID
UniProt ID
Alternative Names
Myosin Binding Protein C, Cardiac; C-Protein, Cardiac Muscle Isoform; Truncated Cardiac Myosin-Binding Protein C; Myosin-Binding Protein C, Cardiac-Type; Myosin-Binding Protein C, Cardiac; Cardiac MyBP-C
Function
Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands. In vitro it binds MHC, F-actin and native thin filaments, and modifies the activity of actin-activated myosin ATPase. It may modulate muscle contraction or may play a more structural role.
Biological Process
Cardiac muscle contraction Source: BHF-UCL
Cell adhesion Source: UniProtKB-KW
Heart morphogenesis Source: BHF-UCL
Positive regulation of ATP-dependent activity Source: BHF-UCL
Regulation of muscle filament sliding Source: BHF-UCL
Regulation of striated muscle contraction Source: BHF-UCL
Ventricular cardiac muscle tissue morphogenesis Source: HGNC-UCL
Cellular Location
Cytosol
Other locations
A band
C zone
cardiac myofibril
sarcomere
striated muscle myosin thick filament
Involvement in disease
Cardiomyopathy, familial hypertrophic 4 (CMH4):
A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Cardiomyopathy, dilated 1MM (CMD1MM):
A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. MYBPC3 mutations may be involved in restrictive cardiomyopathy (RCM), a rare non-ischemic myocardial disease. RCM is characterized by restrictive ventricular-filling physiology in the presence of normal or reduced diastolic and/or systolic volumes (of 1 or both ventricles), biatrial enlargement, and normal ventricular wall thickness.
Left ventricular non-compaction 10 (LVNC10):
A form of left ventricular non-compaction, a cardiomyopathy due to myocardial morphogenesis arrest and characterized by a hypertrophic left ventricle, a severely thickened 2-layered myocardium, numerous prominent trabeculations, deep intertrabecular recesses, and poor systolic function. Clinical manifestations are variable. Some affected individuals experience no symptoms at all, others develop heart failure. In some cases, left ventricular non-compaction is associated with other congenital heart anomalies. LVNC10 is an autosomal dominant condition.
PTM
Substrate for phosphorylation by PKA and PKC. Reversible phosphorylation appears to modulate contraction (By similarity).
Polyubiquitinated.

Carrier, L. (2021). Targeting the population for gene therapy with MYBPC3. Journal of Molecular and Cellular Cardiology, 150, 101-108.

Helms, A. S., Thompson, A. D., Glazier, A. A., Hafeez, N., Kabani, S., Rodriguez, J., ... & Day, S. M. (2020). Spatial and functional distribution of MYBPC3 pathogenic variants and clinical outcomes in patients with hypertrophic cardiomyopathy. Circulation: Genomic and Precision Medicine, 13(5), 396-405.

Helms, A. S., Tang, V. T., O’Leary, T. S., Friedline, S., Wauchope, M., Arora, A., ... & Day, S. M. (2020). Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy. JCI insight, 5(2).

Arif, M., Nabavizadeh, P., Song, T., Desai, D., Singh, R., Bazrafshan, S., ... & Sadayappan, S. (2020). Genetic, clinical, molecular, and pathogenic aspects of the South Asian–specific polymorphic MYBPC3 Δ25bp variant. Biophysical Reviews, 12, 1065-1084.

Toepfer, C. N., Wakimoto, H., Garfinkel, A. C., McDonough, B., Liao, D., Jiang, J., ... & Seidman, C. E. (2019). Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Science translational medicine, 11(476), eaat1199.

Glazier, A. A., Thompson, A., & Day, S. M. (2019). Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy. Pflügers Archiv-European Journal of Physiology, 471, 781-793.

Seeger, T., Shrestha, R., Lam, C. K., Chen, C., McKeithan, W. L., Lau, E., ... & Wu, J. C. (2019). A premature termination codon mutation in MYBPC3 causes hypertrophic cardiomyopathy via chronic activation of nonsense-mediated decay. Circulation, 139(6), 799-811.

O'Leary, T. S., Snyder, J., Sadayappan, S., Day, S. M., & Previs, M. J. (2019). MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy. Journal of molecular and cellular cardiology, 127, 165-173.

Kolokotronis, K., Kühnisch, J., Klopocki, E., Dartsch, J., Rost, S., Huculak, C., ... & Gerull, B. (2019). Biallelic mutation in MYH7 and MYBPC3 leads to severe cardiomyopathy with left ventricular noncompaction phenotype. Human mutation, 40(8), 1101-1114.

Grover, S., Lloyd, R., Perry, R., Lou, P. W., Haan, E., Yeates, L., ... & Selvanayagam, J. B. (2019). Assessment of myocardial oxygenation, strain, and diastology in MYBPC3-related hypertrophic cardiomyopathy: a cardiovascular magnetic resonance and echocardiography study. European Heart Journal-Cardiovascular Imaging, 20(8), 932-938.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Rat Anti-MYBPC3 (AA 2-169) Recombinant Antibody (CBFYM-2876)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry
Happy Thanksgiving
Happy Thanksgiving close ad